Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
Healthcare
$2.00 +1.63%
+$0.10 today
- Market cap
- $109.62M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
52W Low $5.85High $33.68
Volume 0.86M
Average 0.66M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$133.28M
FY 2025 · Annual
Investing Cash Flow
-$93.48M
FY 2025 · Annual
Financing Cash Flow
$2.44M
FY 2025 · Annual
-99.4% YoYCash Flow Statement
USD
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (23.87M) | (20.54M) | (62.81M) | (143.44M) |
| Depreciation & Amortization | 7K | 60K | 89K | (1.31M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.28M | 3.43M | 6M | 10.33M |
| Change in Working Capital | 3.41M | (4.31M) | 1.87M | 589K |
| Accounts Receivables | (412K) | 314K | (515K) | (55K) |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 462K | 1.28M | 2.02M | (1.28M) |
| Other Working Capital | 3.36M | (5.9M) | 371K | 1.93M |
| Other Non-Cash Items | 149K | (16.57M) | (4.33M) | 561K |
| Operating Cash Flow | (19.02M) | (37.93M) | (59.17M) | (133.28M) |
| Capital Expenditures | (82K) | (144K) | (511K) | (165K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (128.99M) | (290.61M) | (385.88M) |
| Sales of Investments | 0 | 46.29M | 231.64M | 292.56M |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (82K) | (82.84M) | (59.49M) | (93.48M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 9.96M | 129.55M | 272.72M | 2.44M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (37K) | 118K | (3.74M) | 0 |
| Financing Cash Flow | 9.96M | 129.55M | 418.91M | 2.44M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (9.14M) | 8.78M | 300.25M | (224.31M) |
| Free Cash Flow | (19.1M) | (38.07M) | (59.68M) | (133.28M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$143.4M
+ D&A-$1.3M
+ Stock-Based Comp$10.3M
+ Deferred Tax$0
+ Working Capital$589.0K
+ Other Non-Cash$561.0K
= Operating Cash Flow-$133.3M
- Capex-$165.0K
= Free Cash Flow-$133.3M
Analysis
FY2025 free cash flow is -$133.3M. FCF conversion is 92.9% of net income. Operating cash flow was -$133.3M, with capex of -$165.0K. The largest bridge item is Stock-Based Comp at $10.3M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 29, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 17, 2026 |
Does UPB generate free cash flow?
Upstream Bio, Inc. (UPB) generated -$133.28M of free cash flow in fiscal 2025.
How much operating cash flow does UPB produce?
Operating cash flow was -$133.28M, before capital expenditures of $165,000.00.
Continue the stock analysis
Jump to another research area for this company.